Filing Details

Accession Number:
0000921895-14-000398
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-02-20 20:00:23
Reporting Period:
2014-02-18
Filing Date:
2014-02-20
Accepted Time:
2014-02-20 20:00:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
886163 Ligand Pharmaceuticals Inc LGND Pharmaceutical Preparations (2834) 770160744
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
918923 P L Fund Value Biotechnology 900 N. Michigan Avenue, Suite 1100
Chicago IL 60611
No No No Yes
1055947 P/Il L Partners Bvf C/O Grosvenor Capital Management
900 N. Michigan Avenue, Suite 1100
Chicago IL 60611
No No Yes No
1056807 Bvf Inc/Il C/O Grosvenor Capital Management
900 N. Michigan Avenue, Suite 1100
Chicago IL 60611
No No Yes No
1102444 Biotechnology Value Fund Ii Lp C/O Grosvenor Capital Management
900 N. Michigan Avenue, Suite 1100
Chicago IL 60611
No No No Yes
1132245 Bvf Investments Llc C/O Grosvenor Capital Management
900 N. Michigan Avenue, Suite 1100
Chicago IL 60611
No No No Yes
1233837 Investment 10 Llc C/O Grosvenor Capital Management Lp
900 N. Michigan Avenue, Suite 1100
Chicago IL 60611
No No No Yes
1233840 N Mark Lampert One Sansome Street
31St Floor
San Francisco CA 94104
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.001 Par Value Disposition 2014-02-18 16,915 $74.66 307,921 No 4 S Indirect By Biotechnology Value Fund, L.P.
Common Stock, $0.001 Par Value Disposition 2014-02-18 16,331 $74.66 174,636 No 4 S Indirect By Biotechnology Value Fund II, L.P.
Common Stock, $0.001 Par Value Disposition 2014-02-18 153,751 $74.66 1,855,083 No 4 S Indirect By BVF Investments, L.L.C.
Common Stock, $0.001 Par Value Disposition 2014-02-18 14,003 $74.66 87,520 No 4 S Indirect By Investment 10, L.L.C.
Common Stock, $0.001 Par Value Disposition 2014-02-19 9,464 $73.03 298,457 No 4 S Indirect By Biotechnology Value Fund, L.P.
Common Stock, $0.001 Par Value Disposition 2014-02-19 5,395 $73.03 169,241 No 4 S Indirect By Biotechnology Value Fund II, L.P.
Common Stock, $0.001 Par Value Disposition 2014-02-19 57,370 $73.03 1,797,713 No 4 S Indirect By BVF Investments, L.L.C.
Common Stock, $0.001 Par Value Disposition 2014-02-19 2,771 $73.03 84,749 No 4 S Indirect By Investment 10, L.L.C.
Common Stock, $0.001 Par Value Disposition 2014-02-20 18,615 $73.05 279,842 No 4 S Indirect By Biotechnology Value Fund, L.P.
Common Stock, $0.001 Par Value Disposition 2014-02-20 10,557 $73.05 158,684 No 4 S Indirect By Biotechnology Value Fund II, L.P.
Common Stock, $0.001 Par Value Disposition 2014-02-20 112,369 $73.05 1,685,344 No 4 S Indirect By BVF Investments, L.L.C.
Common Stock, $0.001 Par Value Disposition 2014-02-20 5,359 $73.05 79,390 No 4 S Indirect By Investment 10, L.L.C.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Biotechnology Value Fund, L.P.
No 4 S Indirect By Biotechnology Value Fund II, L.P.
No 4 S Indirect By BVF Investments, L.L.C.
No 4 S Indirect By Investment 10, L.L.C.
No 4 S Indirect By Biotechnology Value Fund, L.P.
No 4 S Indirect By Biotechnology Value Fund II, L.P.
No 4 S Indirect By BVF Investments, L.L.C.
No 4 S Indirect By Investment 10, L.L.C.
No 4 S Indirect By Biotechnology Value Fund, L.P.
No 4 S Indirect By Biotechnology Value Fund II, L.P.
No 4 S Indirect By BVF Investments, L.L.C.
No 4 S Indirect By Investment 10, L.L.C.
Footnotes
  1. This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), BVF Investments, L.L.C. ("BVLLC"), Investment 10, L.L.C. ("ILL10"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert. (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of his or its pecuniary interest therein.
  2. Shares of Common Stock owned directly by BVF. As the general partner of BVF, Partners may be deemed to beneficially own the shares of Common Stock owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the shares of Common Stock owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the shares of Common Stock owned directly by BVF.
  3. Shares of Common Stock owned directly by BVF2. As the general partner of BVF2, Partners may be deemed to beneficially own the shares of Common Stock owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the shares of Common Stock owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the shares of Common Stock owned directly by BVF2.
  4. Shares of Common Stock owned directly by BVLLC. As the manager of BVLLC, Partners may be deemed to beneficially own the shares of Common Stock owned directly by BVLLC. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the shares of Common Stock owned directly by BVLLC. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the shares of Common Stock owned directly by BVLLC.
  5. Pursuant to the operating agreement of BVLLC, Partners is authorized, among other things, to invest the contributed capital of Samana Capital, L.P., the majority member of BVLLC, in the Common Stock and other securities of the Issuer and to vote, exercise or convert and dispose of such securities and is entitled to receive fees based on assets under management and, subject to certain exceptions, allocations based on realized and unrealized gains on such assets.
  6. Shares of Common Stock owned directly by ILL10. As the investment adviser of ILL10, Partners may be deemed to beneficially own the shares of CommonStock owned directly by ILL10. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the shares ofCommon Stock owned directly by ILL10. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the shares of Common Stockowned directly by ILL10.